Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
PHOENIX and VANCOUVER, British Columbia, June 28, 2017 -- Eternity Healthcare Inc. (OTC:ETAH), announces it has resolved an earlier manufacturing issue affecting 10% of its syringes (nozzles) and resulting in a failure to obtain CE certification and approval. Preliminary testing of a number of nozzles, confirmed compliance with certification standards.
“We are pleased to sort out this final hurdle and look forward to CE auditors completing the inspection process for approval,” said Dr. Salari, President & CEO.
The Lenis® Needle-Free Injection system is comprised of four major components. Currently two of the components have received CE certification and approval and now the third component shall be submitted for approval. We believe the remaining components shall get the approval soon.
Needle-Free Injection System Applications
The Needle-Free Injection system can be used for a vast variety of injectable medications, and supplements. These include injection of Insulin for diabetes, injection of vaccines such as flu vaccine and many others, injection of steroids, vitamins, human growth hormones, infertility medications, a vast number of cancer drugs, cosmetic fillers and a new version of epinephrine drugs such as, Mylan’s Epipen®.
About Eternity Healthcare
Eternity Healthcare or the “Company” (OTC:ETAH) is a medical device company with technologies known as Needle-Free Injection System (the Lenis®). Our products are targeted for use by the healthcare professionals, physicians and consumers directly. For more information on Eternity Healthcare, visit the Company’s website; www.eternityhealthcare.com
Safe Harbor Statement
This release includes forward-looking statements. These statements generally can be identified by phrases such as "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.
Company Contact: Dr. Salari President & CEO (604) 324 -1113 [email protected]
